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Abstract
Background: Sex is recognized as a significant determinant of outcome among glioblastoma patients, but the
relative prognostic importance of glioblastoma features has not been thoroughly explored for sex differences.
Methods: Combining multi-modal MR images, biomathematical models, and patient clinical information, this
investigation assesses which pretreatment variables have a sex-specific impact on the survival of glioblastoma
patients (299 males and 195 females).
Results: Among males, tumor (T1Gd) radius was a predictor of overall survival (HR = 1.027, p = 0.044). Among
females, higher tumor cell net invasion rate was a significant detriment to overall survival (HR = 1.011, p < 0.001).
Female extreme survivors had significantly smaller tumors (T1Gd) (p = 0.010 t-test), but tumor size was not
correlated with female overall survival (p = 0.955 CPH). Both male and female extreme survivors had significantly
lower tumor cell net proliferation rates than other patients (M p = 0.004, F p = 0.001, t-test).
Conclusion: Despite similar distributions of the MR imaging parameters between males and females, there was a
sex-specific difference in how these parameters related to outcomes.
Keywords: Glioblastoma, Neuroimaging, Sex differences, Biomathematical models
Background
Glioblastoma (GBM) is the most common primary malig-
nant brain tumor, with a median overall survival of 9 to 15
months [1–3]. According to Ostrom et al. [4], only 35% of
patients survive more than 1 year and 4.7% of patients sur-
vive more than 5 years after diagnosis. Factors such as age at
diagnosis, Karnofsky performance score (KPS), extent of
surgical resection, and tumor location have been found to
play a significant role in determining the duration of patient
survival [5–7], but there is still limited insight into which
underlying biological features contribute to a patient becom-
ing a “survival outlier.” To date, there is minimal research on
the utility of using pretreatment (pre-tx), image-based volu-
metric and kinetic variables to identify potential extreme and
short-term survivors. Additionally, while it has been consist-
ently identified that GBM incidence is higher among males
[8–12] and females GBM patients have better outcomes [8,
12–14], little to no research has focused on sex-specific pre-
dictors of survival. The ability to pinpoint relevant predictors
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of the duration of overall survival has clinical value and identi-
fies areas for future research. By using variables derived from
patient clinical information and routinely-obtained, non-
invasive MR images, we can establish predictors of survival
duration that can be readily assessed in a pre-tx setting.
Knowing whether these factors affect males and females in
the same way will contribute to guiding research efforts to-
wards best-practice, individualized patient care.
The purpose of this study was to determine whether there
are sex-specific predictors of survival outcomes among glio-
blastoma patients. Using patient data from our multi-
institutional brain tumor repository, we tested the significance
of eight pre-tx volumetric, kinetic, and clinical variables in pre-
dicting extreme and short-term survival. We also tested
whether these variables and additional categorical variables, in-
cluding tumor laterality, extent of resection (EOR), isocitrate
dehydrogenase 1 (IDH1) mutation status, and O(6)-methyl-
guanine-DNA methyltransferase promoter (MGMT) methyla-
tion status, significantly impacted the overall survival of male
and female patients. Throughout the analysis, males and fe-
males were tested separately as distinct population groups and
their results were compared, allowing us to identify sex-
specific impactors of survival outcome among GBM patients.
Methods
Imaging
As described in Swanson et al. [15], tumor volumes were
segmented from MR images [gadolinium-enhanced T1-
weighted (T1Gd), T2-weighted (T2), and T2 fluid-
attenuated inversion recovery (T2-FLAIR)] by trained in-
dividuals using our in-house thresholding-based software.
These volumes were converted to their spherically-
equivalent radii for further analysis.
Biomathematical models and patient-specific tumor
kinetics
An extensive literature has been generated over the last two
decades applying a biomathematical model to simulate
patient-specific glioblastoma growth [15–18]. The primary
model is referred to as the Proliferation-Invasion (PI) model
and is based on two key parameters: the net rate of prolifera-
tion, ϱ, and the net rate of invasion, D (Fig. 1). These estimates
have been shown to be prognostic of benefit from resection
[18], survival [16], and radiation efficacy [20] and can be used
to examine therapeutic response [21, 22]. Traditional methods
of calculating PI D and ϱ require two pre-tx time points of im-
aging and these are not always available. We have thus lever-
aged a second model, the Proliferation-Invasion-Hypoxic-
Necrotic-Angiogenesis (PIHNA) model [23], which incorpo-
rates necrosis to estimate D and ϱ using one image time point.
For more detail, refer to supplement 16 and 17.
Patient population
Our research lab has amassed a large multi-institutional re-
pository consisting of the clinical patient data and serial,
multi-modal MR images of over 1400 glioblastoma patients.
From this repository, we identified all newly-diagnosed glio-
blastoma patients with necessary clinical information (sex,
age, and overall survival) and a calculated pre-tx (prior to bi-
opsy or resection) tumor volume from a T1Gd MRI. This
cohort was comprised of 494 primary GBM patients (299
males and 195 females). Since the calculation of PIHNA D,
PIHNA ϱ, and PI D/ϱ requires both T1Gd and T2 or T2-
FLAIR (T2/FLAIR) images, a sub-cohort of patients with suf-
ficient imaging was created from the main cohort in order to
study the effect of these variables on survival (223 males and
141 females).
Fig. 1 Schematic of determination and interpretation of patient-specific tumor kinetic parameters. Left: After tumors are segmented on T1Gd and
T2/FLAIR images, the volumes of the imaging abnormalities are used to calculate the spherically-equivalent tumor radii. By assuming the volume
seen on T1Gd corresponds to a high cell density and that on T2/FLAIR to a lower cell density, the relative sizes of the abnormalities on these two
imaging modalities gives an estimated profile or slope of the tumor cell density. The ratio of our biomathematical model parameters D/ϱ is a
way to quantify this profile. Right: A tumor that has relatively more diffuse invasion compared to tumor cell proliferation (high D/ ϱ) is expected
to have a more diffuse distribution of cell density. Conversely, a tumor with relatively more cell proliferation than diffuse invasion (low D/ϱ) is
expected to have a more nodular distribution of cell density (red = high tumor cell density, blue = low tumor cell density). Adapted from Baldock
et al. 2014 [17] with permission from Oxford University Press (right) and Corwin et al. 2013 [19] (left)
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We defined extreme survivors (EXS) as those with
overall survival (OS) of 5 years (1825 days) or longer.
EXS typically make up less than 5% of glioblastoma pa-
tients [4]. However, due to the data collection efforts of
a multicenter collaboration researching extreme survival
among GBM patients (ENDURES), about 9.5% of pa-
tients in this cohort were EXS. When the EXS patients
were added to the repository, their medical records were
reviewed to confirm the diagnosis of GBM. EXS were
compared to Non-EXS (OS< 1825 days). We also com-
pared short-term survivors (STS) (OS≤210 days) [24]
and Non-STS (OS> 210 days). The breakdown of the
main cohort and the sub-cohort by sex and survival
group is shown in Table 1.
Statistical analysis
Table 2 outlines the eight quantitative volumetric, kin-
etic, and clinical variables that were explored in our in-
vestigation. Two-sided Student’s t-tests with Welch’s
corrections were used to test whether there were signifi-
cant differences in the eight quantitative variables be-
tween the survival groups. Two-sided Cox-Proportional
Hazards models (CPH) were used to assess which of the
quantitative variables were significant predictors of OS.
Parameters that were significant or almost significant
(p < 0.10) in univariate analysis were compared in multi-
variate analysis. Kaplan-Meier survival analysis (two-
sided log-rank tests) and CPH models were used to as-
sess the impact of the categorical variables on survival.
The following categorical variables were included: IDH1
mutation status, MGMT methylation status, tumor lat-
erality, and EOR. T-tests and Kaplan-Meier survival
curves were generated using Prism [25] and the CPH
models were generated using R studio [26]. All statistical
analyses were performed separately for the male and fe-
male populations. There was no significant difference in
the distribution or mean values of these variables be-
tween males and females (Supplement 11).
Decision trees
The decision trees (DT) in this study were created using
R [26], accompanied by a package called rpart [27],
which allows effective decision tree pruning. Six DT
were produced in total, grouped into 3 pairs. Within
each pair, one tree was created using the male popula-
tion and the other was created using the female popula-
tion. The PI and PIHNA subcohort of patients (223 males
and 141 females) was used to create the training (70% of
population) and testing (30%) groups and 10-fold cross
validation was used to ensure the generalizability of the re-
sults. For each tree, accuracy and sensitivity (EXS and STS
are considered condition positive) are reported for the
training group, testing group, and the full cohort (training
+ testing). All six trees were constructed using the eight
quantitative pre-tx variables: age, T1Gd radius, necrosis
radius, CE thickness, T2/FLAIR radius, PIHNA D, PIHNA
ϱ, and PI D/ϱ.
Study approval
All featured patients either provided informed consent
or were approved for retrospective research before inclu-
sion in this investigation. All methods were carried out
in accordance with the relevant guidelines and regula-
tions. All experimental protocols, including the usage
and collection of patient data, were carried out under
Mayo Clinic institutional review board approvals.
Results
Variables associated with extreme and short-term survival
Student’s t-tests were performed separately on males
and females and compared the following groups: EXS vs
Non-EXS, EXS vs STS, and STS vs Non-STS. The re-
sults of this analysis can be found in Table 3. When
compared to the rest of the male population, EXS were
significantly younger (p = 0.005) and STS were signifi-
cantly older (p < 0.001). Male EXS had significantly
smaller ϱ when compared to male Non-EXS (p = 0.004).
When compared to the rest of the female population, fe-
male EXS were significantly younger (p = 0.032) while fe-
male STS were significantly older (p < 0.001). Female
EXS had significantly smaller T1Gd radii compared to
female Non-EXS (p = 0.010). Compared to the rest of
the female population, female EXS had significantly
smaller D (p = 0.008) and female STS had significantly
larger D (p = 0.018). Female EXS had significantly
smaller ϱ compared to female Non-EXS (p = 0.001).
Table 1 Breakdown of the main cohort and sub-cohort by sex and survival group. Percentages indicate the distribution of males
and females in each survival group






Male Female Male Female
All Patients 299 (60.5%) 195 (39.5%) 223 (61.2%) 141 (38.7%)
Extreme (OS > 1825 days) 30 (63.8%) 17 (36.2%) 26 (70.3%) 11 (29.7%)
Short term (OS < 210 days) 46 (52.3%) 42 (47.7%) 32 (50%) 32 (50%)
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In the female EXS vs Non-EXS DT (Fig. 2a and b), the
nodes that predicted EXS with 100% sensitivity included
T1Gd radius < 21.93mm and age < 28.5 years. Notably, all
male EXS had CE thickness shorter than 11.33mm, PI D/
ϱ above 0.3687mm2, and age below 72 years. In the female
EXS vs STS DT (Fig. 2c and d), the nodes that best pre-
dicted female EXS included ϱ < 10.33 year − 1 and CE
thickness < 4.746mm and the node that best predicted fe-
male STS was age ≥ 47.5 years. In the male DT, the node
that best predicted EXS was ϱ < 118.2 year − 1 and the
node that best predicted STS was D ≥ 11.85mm2/year.
The third pair of DT sorted males and females into STS
and Non-STS groups (Fig. 2e and f). Among females, the
nodes that best predicted STS included age ≥ 49.5 years,




Mean Median Range Mean Median Range
Age
(years)
Age of patient on date of diagnosis 57.58 58 12–95 58.41 60.5 9–96
T1Gd Radius
(mm)
Combined volume of the central non-enhancing necrotic region and sur-
rounding enhanced region of tumor in a pre-tx T1Gd MR image (con-







Volume of non-enhancing central necrotic region in a pre-tx T1Gd MR







Average linear thickness of the contrast-enhancing region in a pre-tx T1Gd




























Table 3 Results of the t-test comparisons of the eight quantitative volumetric and clinical variables between the survival groups for
males and females. Purple boxes indicate that the means of the variables were significantly different between the survival groups
within both the male and female populations. Red boxes indicate a significant difference within the female population and blue
indicate a significant difference within the male population. Gray boxes indicate that neither population showed a significant
difference in the means of the variables between the survival groups. Detailed results of t-tests can be found in Supplement 13
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T2/FLAIR radius ≥ 23.76mm, and D ≥ 41.23mm2/year. In
the male DT, the nodes that most accurately predicted
STS included age ≥ 47.5 years, ϱ ≥ 10.33 year − 1, and CE
thickness between 11.25mm and 12.36mm.
Variables associated with overall survival
Univariate and multivariate CPH analyses (Table 4) were
utilized to determine which variables significantly influ-
enced the overall survival of GBM patients. Variables
that were significant or almost significant (p < 0.10) in
univariate analysis were analyzed in multivariate analysis.
In the male multivariate CPH, factors found to inde-
pendently influence survival included: age (HR = 1.030,
p < 0.001) and T1Gd radius (HR = 1.027, p = 0.044). In
the female multivariate CPH analysis, age (HR = 1.021,
p = 0.006) and PIHNA D (HR = 1.011, p < 0.001) were
identified as significant independent prognostic factors.
IDH1 mutation
Since IDH1 mutation has been previously identified as
significant predictor of long-term survival [14], we ana-
lyzed the impact of sex and IDH1 status on the overall
Fig. 2 Decision trees binning male and female EXS, Non-EXS, STS, and Non-STS based on patient and tumor characteristics. At each node, color
(green for EXS, gray for Non-EXS, black for STS, and blue for Non-STS) and percentages indicate concentration of each group. a Female EXS vs
Non-EXS DT (n = 141). b Male EXS vs Non-EXS DT (n = 223). c Female EXS vs STS DT (n = 43). d Male EXS vs STS (n = 58). e Female STS vs Non-STS
DT (n = 141). f Male STS vs Non-STS DT (n = 223)
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survival of our patient cohort. Among the 120 patients in
the main cohort that had available IDH1 status, there were
69 wild-type (wt) and 8 mutant (mut) male patients and
39 wt and 4 mut female patients. When analyzing the en-
tire population (both males and females), there was a
trend towards IDH1 mut patients having better survival
(log-rank, p = 0.071). Among females, IDH1 mut survived
significantly longer than IDH1 wt patients (log-rank, p =
0.008), but among males, the survival difference was not
significant (log-rank, p = 0.924) (Supplement 1). This ana-
lysis is limited by the small cohort of IDH1 mut patients,
but it was notable that all 4 IDH1 mut females survived at
least 3 years, making them all long-term survivors [28].
MGMT methylation
Methylation of the MGMT promoter has been found to
be more common in long-term survivors [29], so we also
assessed the impact of MGMT methylation on the sur-
vival of our population cohort. Ninety patients from the
main cohort had available MGMT methylation status,
which comprised of 32 females (12 methylated and 20
unmethylated) and 58 males (18 methylated and 40
unmethylated). Methylated patients had significantly bet-
ter survival than unmethylated patients among males (log-
rank, p = 0.013), females (p = 0.007), and the entire popu-
lation (males and females) (p < 0.001) (Supplement 4).
Multivariate CPH analyses that assessed the impact of
MGMT status on survival while accounting for age
showed that MGMT status significantly impacted survival
for males (p = 0.004) and females (p = 0.037). Among EXS
with available MGMT methylation status (n = 15), 50%
(n = 5) of males and 60% (n = 3) of females had MGMT
methylation, while among Non-EXS (n = 75), 29% (n = 14)
of males and 33% (n = 9) of females had MGMT methyla-
tion, suggesting that MGMT methylation was more com-
mon among both male and female EXS.
Laterality
Using pre-tx T1Gd MR images, we determined the lateral-
ity of each patient’s tumor, classifying the tumors as being
located in the right hemisphere, left hemisphere, or both
hemispheres (bilateral). The impact of tumor laterality on
survival was assessed separately for males and females,
and the results were compared. Among males, there were
129 left hemisphere GBMs, 154 right hemisphere GBMs,
and 11 bilateral GBMs, and among females there were 86
left hemisphere GBMs, 96 right hemisphere GBMs, and 9
bilateral GBMs. Laterality could not be determined for 5
male and 4 female patients.
Male patients with tumors on the left side tended to
have better survival than males with tumors on the right
side (log-rank, p = 0.077) and had significantly better
survival than males with bilateral tumors (p = 0.010)
(Supplement 6). In a multivariate CPH analysis that also
Table 4 Results of univariate and multivariate CPH analyses for males and females. Factors that were almost significant (p < 0.10) or
significant in univariate analysis were included in the multivariate analysis
Univariate Multivariate
Covariate HR 95% CI p-value HR 95% CI p-value
Males
Age 1.027 1.018–1.037 < 0.001 1.030 1.017–1.044 < 0.001
Necrosis radius 1.018 0.996–1.040 0.118 N/A
T1Gd radius 1.024 1.003–1.046 0.025 1.027 1.001–1.054 0.044
CE Thickness 1.028 0.989–1.068 0.161 N/A
T2/FLAIR radius 0.996 0.972–1.020 0.744 N/A
PIHNA D 1.003 0.997–1.010 0.266 N/A
PIHNA ϱ 1.001 1.000–1.001 0.064 1.000 0.999–1.001 0.637
PI D/ϱ 0.932 0.872–0.996 0.038 0.951 0.880–1.029 0.210
Females
Age 1.028 1.015–1.041 < 0.001 1.021 1.006–1.037 0.006
Necrosis radius 1.017 0.991–1.042 0.204 N/A
T1Gd radius 1.026 1.000–1.052 0.048 0.993 0.964–1.023 0.641
CE Thickness 1.037 0.988–1.088 0.143 N/A
T2/FLAIR radius 1.017 0.989–1.045 0.232 N/A
PIHNA D 1.011 1.006–1.016 < 0.001 1.011 1.005–1.017 < 0.001
PIHNA ϱ 1.001 1.000–1.002 0.052 1.000 0.999–1.002 0.801
PI D/ϱ 0.996 0.937–1.059 0.906 N/A
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accounted for extent of resection, tumor location in the
left hemisphere was found to be a significant independ-
ent predictor of improved survival outcome for males
(p = 0.017) (Supplement 14). There were more EXS than
STS among males with tumors on the left side and there
were almost twice as many STS as EXS among males
with tumors on the right side. Laterality did not have a
significant impact on survival for female patients (CPH,
p = 0.299) (Supplement 14). There was no significant dif-
ference in survival between females with left and right
hemisphere tumors (log-rank, p = 0.218), and females
with bilaterally located tumors did not have significantly
worse survival when compared to females with non-
bilateral tumors (bilateral vs left p = 0.272, bilateral vs
right p = 0.471) (Supplement 6).
Extent of resection
Our investigation evaluated whether the extent of initial
surgical intervention, a known prognostic factor among
GBM patients, had the same prognostic value for both
male and female GBM patients. Patient EOR status, cate-
gorized as gross total resection (GTR), subtotal resection
(STR), or biopsy, was obtained from the patient records.
From the main cohort of 494 patients, 211 males (83
GTR, 83 STR, and 45 biopsy) and 136 females (54 GTR,
55 STR, and 27 biopsy) had available EOR status.
EOR had a significant impact on the survival of male
GBM patients. GTR males had significantly better survival
than STR males (log-rank, p= 0.033) (Supplement 9) and
males who received some surgical resection (GTR or STR)
had significantly better survival than males who only received
a biopsy (p= 0.013) (Supplement 8). Cochran-Armitage
Trend Test showed that there was significant trend towards
male EXS receiving more extensive resections and male STS
receiving less extensive resections or biopsies (p= 0.027). Fe-
male who received resection (GTR or STR) trended towards
improved survival compared to biopsy females (log-rank,
p= 0.077) (Supplement 8), but there was no significant dif-
ference in survival between GTR females and STR females
(p= 0.992) (Supplement 9). Additionally, EOR did not signifi-
cantly impact female survival in univariate CPH analysis
(p= 0.180) (Supplement 14). Trend test showed that there
was an insignificant trend towards female EXS receiving
more extensive resections and female STS receiving less ex-
tensive resections or biopsies (p= 0.098).
Patients receiving current standard of care
Due to the timespan over which they were collected, the
patients in our cohort received a wide variety of treat-
ment protocols. In order to ensure that our results
maintain significance among patients who receive the
current standard of care (maximal safe resection
followed by concurrent temozolomide and radiation
therapy), we created a subset of patients who received
this treatment protocol (Stupp protocol patients) [30]
and tested which factors were associated with overall
survival among those patients (Supplement 15). In this
limited subpopulation, we had 113 males and 66 females
(Supplement 15A). Among females, PIHNA D was a sig-
nificant independent predictor of overall survival and
among males, PIHNA ϱ was a significant independent
predictor of overall survival (Supplement 15B).
Discussion
While there are no differences in the distributions of
these quantitative and categorical variables between
males and females, this investigation found that there
are sex-specific differences in the impact that these vari-
ables have on patient survival (Fig. 3).
Impact of quantitative variables on survival
Tumor cell diffuse invasion rate (PIHNA D) is strongly
negatively correlated with overall survival for females across
the various analyses and is not consistently significant for
males. Notably, both when EOR was included in multivari-
ate CPH analysis (Supplement 14) and when only Stupp
protocol patients were considered (Supplement 15B),
PIHNA D was still an independent predictor of survival for
females. Although it was not significant in the CPH multi-
variate analysis, it is notable that males had a significant
positive association between overall survival and PI D/ϱ in
univariate analysis (Table 4). This suggests that more nodu-
lar tumors at time of diagnosis are associated with worse
prognosis for males, which is contrary to the finding that
more diffusely invasive tumors are associated with worse
prognosis for females.
Among males, total tumor size (T1Gd radius) is negatively
correlated with overall survival across the statistical analyses
(Tables 3 and 4). In the DT analyses, CE thickness, a compo-
nent of total tumor size, is a highly sensitive predictor of sur-
vival outcome (Fig. 2b and f). While total tumor size is not
continuously associated with survival for females in the same
way that it is for males, smaller total tumor size (T1Gd ra-
dius) is significantly associated with EXS for females. DT
analysis showed that nodes isolating females with below
average necrosis radii and CE thickness, both components of
overall tumor size, were highly sensitive predictors of EXS
(Fig. 2a and c). When the mean T1Gd radius of EXS was
compared to the mean T1Gd radius of other survival groups,
the mean radius of EXS was significantly smaller (Table 3).
Univariate CPH found that T1Gd radius size was a signifi-
cant predictor of survival for females (Table 4), but if EXS
were excluded from the analysis, this relationship is no lon-
ger significant (p= 0.503). These results suggest female ex-
treme survivors have smaller pre-tx T1Gd radii, but T1Gd
radius is not negatively correlated with overall survival for fe-
males in general.
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Age is known to have a significant impact on the sur-
vival of glioblastoma patients [5–7] and this analysis
confirmed that age significantly impacts the survival of
both males and females. Across the analyses, older age
at time of diagnosis is consistently associated with
shorter survival, while younger age is associated with
longer survival (Tables 3 and 4).
Lower tumor cell proliferation rates (PIHNA ϱ) are as-
sociated with EXS for both males and females. DT ana-
lysis and statistical analysis both showed that low
proliferation rates were associated with EXS (Table 3
and Fig. 2c and d). Low tumor cell proliferation rates ap-
pear to be predictive of long-term survival for both
males and females, but high rates do not appear to pre-
dict short-term survival.
Impact of categorical variables on survival
While Schiffgens et al. [32] found that only IDH1 mu-
tant males demonstrate significantly improved survival
compared to IDH1 wild-type males, our investigation
found the opposite, that only IDH1 mutant females
demonstrate significantly improved survival when com-
pared to their wild-type counterparts (Supplement 1).
While our investigation into this matter is limited by a
small cohort of IDH1 mutants, our finding is in concur-
rence with the findings of Yang et al. [33], who grouped
females by genetic similarities and found that the
longest-living female cohort predominantly consisted of
IDH1 mutant females. They did not see this effect for
males. The findings of Schiffgens et al. [32] and Yang
et al. [33] make a compelling case for the need to con-
sider sex in IDH1-related research.
Previous studies have demonstrated that MGMT pro-
moter methylation is a significant independent prognos-
tic factor [34] and is more common among long-term
survivors [29, 35]. Despite having a small sample of pa-
tients with known MGMT methylation status, our ana-
lysis was able to confirm that, for both males and
females, MGMT methylation was more common among
extreme survivors and was a significant independent
prognostic factor. Previous studies have also found that
the survival benefit of MGMT methylation was stronger
or only significant among female patients [32, 36], but
our analysis did not see any evidence of females benefit-
ing more from MGMT methylation than males.
In this investigation, GBM laterality impacted male
survival, but had no impact on female survival. Even
after accounting for EOR, males with tumors located in
the left hemisphere had a significant survival advantage
compared to males with tumors located in the right
hemisphere. Ellingson et al. [37] found that patients who
responded favorably to chemotherapy, patients with pro-
longed survival, and patients with specific genetic modi-
fications, like MGMT promoter methylation and IDH1
mutation, had tumors that clustered in areas of the left
hemisphere of the brain. Additional research will need
to be conducted on the relationship between genetic
modifiers, laterality, sex, and survival.
Previous literature has identified extent of resection as
a significant predictor of overall survival for GBM pa-
tients [6, 18, 38, 39], but whether EOR has the same im-
pact on survival for males and females has not been
clearly elucidated. Our analysis found that EOR has a
significant impact on the survival of male GBM patients,
with a more complete resection being associated with
longer survival and potentially extreme survival. Among
females, there was a survival benefit associated with re-
ceiving resection, but the extent of resection did not
have a significant impact on survival. These findings sug-
gest that EOR may have a sex-specific impact on sur-
vival, but further study will be required to fully
understand the extent of this difference.
Limitations and further work
Due to the utilization of retrospective clinical data, it
was not possible to control for all confounding factors
and bias within our dataset. Some of the factors
Fig. 3 Sex differences in the impact of image-based parameters on
survival [31]. The differences between the connections of the red
and blue ribbons represent sex differences in the prognostic
significance of image-based tumor and patient characteristics. The
bottom portion of the outer ring lists the relevant quantitative
variables and the top portion shows the three aspects of survival
that are associated with these variables (EXS, STS, and Overall
Survival). Red ribbons indicate significant relationships for female
patients between the parameter and the survival group and blue
ribbons indicate significant relationships for male patients. Variables
that were significant in multivariate CPH are connected to the
Overall Survival segment and variables that were significant in
Student t-tests with Welch’s correction are connected to the
relevant EXS or STS segments
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contributing to the heterogeneity of our cohort include
the variety of institutions where patients were treated,
the span of the years over which the patients were
treated, the relatively small subset of patients with test-
ing for molecular markers, the variety of treatment pro-
tocols given to our patients, and the inclusion of IDH1
mutated glioblastomas within our cohort [40]. Our
utilization of a large cohort of almost 500 patients allows for
the mitigation of some of these confounding effects and a
sub-analysis of patients with the same treatment protocol
largely confirmed the results from the full cohort, but further
study is needed to validate the results of this study. Once val-
idated, further basic biological and prospective clinical inves-
tigations will be necessary to elucidate the mechanism and
clinical implication of these observed differences.
Conclusion
Taken together, these results emphasize the need to
consider sex as a relevant biological factor in all
glioblastoma-related research. Sex has been shown to
play a significant role in many clinically relevant aspects
of GBM, and yet, many studies do not report patient sex
and those that do often do not consider sex when ana-
lyzing their results. The consideration of the role of sex
in tumor behavior, incidence, growth, and treatment re-
sponse will only lead to higher-quality, more individual-
ized knowledge and care for glioblastoma patients.
Supplementary information
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